Advertisement
News
Advertisement

Biogen releases more positive data for oral MS drug

Fri, 10/12/2012 - 12:00am
Mass High Tech: The Journal of New England Technology

Biogen Idec (NASDAQ: BIIB) is awaiting approval from the U.S. Food and Drug Administration for its first oral multiple sclerosis therapy, and has released new Phase 3 data that shows positive efficacy and safety for the drug candidate. The FDA is scheduled to make a decision on or before Dec. 28.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading